Monopar Therapeutics Inc. (NASDAQ:MNPR) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Monopar Therapeutics Inc. (NASDAQ:MNPR) have received a consensus rating of “Moderate Buy” from the six ratings firms that are currently covering the stock, Marketbeat reports. One research analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $60.00.

Several equities research analysts have commented on MNPR shares. HC Wainwright reissued a “buy” rating and issued a $40.00 target price on shares of Monopar Therapeutics in a report on Tuesday, April 1st. Jones Trading restated a “hold” rating on shares of Monopar Therapeutics in a research note on Wednesday, April 2nd. Chardan Capital started coverage on Monopar Therapeutics in a research note on Monday, June 23rd. They issued a “buy” rating and a $60.00 price target for the company. Wall Street Zen upgraded Monopar Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, May 22nd. Finally, Cantor Fitzgerald started coverage on Monopar Therapeutics in a research note on Monday, July 7th. They issued an “overweight” rating and a $74.00 price target for the company.

Monopar Therapeutics Price Performance

Shares of Monopar Therapeutics stock opened at $47.25 on Friday. Monopar Therapeutics has a 1 year low of $1.72 and a 1 year high of $54.30. The firm has a market cap of $289.17 million, a PE ratio of -13.58 and a beta of 1.01. The stock has a fifty day moving average price of $35.73 and a 200-day moving average price of $36.04.

Monopar Therapeutics (NASDAQ:MNPR) last announced its quarterly earnings data on Tuesday, May 13th. The company reported ($0.38) earnings per share for the quarter, topping the consensus estimate of ($0.65) by $0.27. As a group, equities analysts anticipate that Monopar Therapeutics will post -1.65 EPS for the current fiscal year.

Insider Transactions at Monopar Therapeutics

In other Monopar Therapeutics news, CEO Chandler Robinson sold 16,800 shares of Monopar Therapeutics stock in a transaction dated Monday, July 14th. The stock was sold at an average price of $40.00, for a total transaction of $672,000.00. Following the completion of the transaction, the chief executive officer owned 73,472 shares in the company, valued at approximately $2,938,880. This trade represents a 18.61% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Christopher M. Starr sold 16,800 shares of Monopar Therapeutics stock in a transaction dated Monday, July 14th. The shares were sold at an average price of $40.00, for a total value of $672,000.00. Following the transaction, the director owned 5,173 shares of the company’s stock, valued at $206,920. The trade was a 76.46% decrease in their position. The disclosure for this sale can be found here. Insiders sold 42,504 shares of company stock valued at $1,700,160 in the last quarter. 20.50% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Monopar Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. AlphaQuest LLC acquired a new position in Monopar Therapeutics in the first quarter valued at approximately $44,000. JPMorgan Chase & Co. acquired a new position in Monopar Therapeutics in the fourth quarter valued at approximately $45,000. Gerber LLC acquired a new position in Monopar Therapeutics in the first quarter valued at approximately $204,000. OMERS ADMINISTRATION Corp acquired a new position in Monopar Therapeutics in the first quarter valued at approximately $328,000. Finally, Jane Street Group LLC acquired a new position in Monopar Therapeutics in the first quarter valued at approximately $377,000. Hedge funds and other institutional investors own 1.83% of the company’s stock.

Monopar Therapeutics Company Profile

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.